– Additional Phase 2b data evaluating AD109 as potential treatment for OSA anticipated in Q3 2022 – AD109 Phase 3 development program expected to be initiated in late 2022 CAMBRIDGE, Mass. June 28, 2022 – Apnimed, a clinical-stage pharmaceutical company focused on...
CAMBRIDGE, Mass. June 16, 2022 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders, announced today that Ruoxi (Rosy) Hu, Ph.D., from Morningside...
CAMBRIDGE, Mass. June 6, 2022 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders, today announced that Apnimed will participate in the Jefferies...
– Results support further clinical study of AD504 in OSA patients – Data to be presented at SLEEP 2022, the annual meeting of the Associated Professional Sleep Societies CAMBRIDGE, Mass. June 2, 2022 – Apnimed, a clinical-stage pharmaceutical company focused on...
– Sectoral Asset Management led the round, with participation from new and existing investors – Proceeds will enable Apnimed to initiate its planned Phase 3 development program for the company’s lead OSA candidate, AD109 CAMBRIDGE, Mass. May 4, 2022 – Apnimed, a...
CAMBRIDGE, Mass. April 5, 2022 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders, today announced that company management will participate in 1×1...
